AIM Vaccine Co., Ltd.
艾美疫苗股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 06660)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025

Reference is made to the annual results announcement for the year ended December 31, 2025 (the "**Announcement**") of AIM Vaccine Co., Ltd. (the "**Company**", and together with its subsidiaries, the "**Group**") dated March 30, 2026. Unless otherwise stated, capitalized terms used herein shall have the same meanings as defined in the Announcement.

As disclosed in the Announcement, impairment losses on other intangible assets and impairment losses on property and equipment were recorded for the financial year ended December 31, 2025 due to, among others, the suspension of the R&D projects for mRNA human rabies vaccine and mRNA veterinary vaccine by a subsidiary of the Company; and the delay in the commercialization timeline of the 13-valent pneumococcal conjugate vaccine ("**PCV13**"). The Company hereby provides following further information in this regard.

AIM Liverna's intangible assets

The Company has continued to monitor the progress of mRNA technology in China in light of domestic policy trends and project advancement requirements, while simultaneously advancing the clinical application processes for the mRNA human rabies vaccine, mRNA RSV vaccine, and mRNA herpes zoster vaccine. In late 2025, after comprehensive evaluation, the Company determined that it would be difficult to obtain the clinical data accumulated from other mRNA vaccine products in the short term as discussed with experts of the Center for Drug Evaluation ("**CDE**"), and decided to temporarily suspend the advancement of the mRNA human rabies vaccine project.

Additionally, given that the market authorization pathway and requirements for the veterinary mRNA rabies vaccine differ significantly from those for the human vaccine, the Company decided to focus on the development of the human vaccine and to suspend the veterinary mRNA rabies vaccine project. Due to the aforementioned multiple factors, there are significant uncontrollable uncertainties regarding the timing of the resumption of R&D for the two mRNA vaccine projects, the probability of regulatory approval, the R&D timeline, the commercialization timeline, and the future economic benefits that may be realized. There is no reliable basis to support any forecast of future earnings.

Accordingly, the management of the Company conducted a prudential reassessment and determined that it is reasonable to exclude the revenue contributions from the mRNA human rabies vaccine and the mRNA veterinary vaccine in the cash flow projections for the impairment test as of December 31, 2025. This adjustment reduced the valuation of deferred development costs from the acquisition by approximately RMB127.9 million.

AIM Persistence's PCV13 Development Expenditures

The significant change in the valuation of development costs primarily stems from adjustments to projected revenue and R&D expenses in the cash flow projections.

In December 2025, after comprehensive evaluation, the Company submitted an application to withdraw the NDA materials to the CDE and the Board was informed of the delay in the commercialization timeline for PCV13. Due to the delayed market launch and the impact of multiple factors related to the supplemental studies, the commercialization timeline for the PCV13 R&D project has been correspondingly postponed, resulting in changes in the market environment, competitive landscape, and future expected economic benefits.

Accordingly, the management of the Company conducted a prudent reassessment and determined that it was reasonable to reduce the projected revenue from the PCV13 vaccine in the cash flow projections for the impairment test as of December 31, 2025. Additionally, due to the need to conduct supplementary studies, R&D expenses have increased significantly. These adjustments resulted in a reduction of approximately RMB83.23 million in the valuation of development expenditures.

AIM Persistence's Pneumococcal-Related Long-Term Assets

Due to the delay in the commercialization of PCV13 and the impairment of development expenditures, the management of the Company conducted a prudent assessment and determined that there were indications of impairment in the related long-term assets. Therefore, based on the profitability forecasts for relevant pneumococcal products, the Company performed its impairment test on the long-term assets related to the pneumococcal vaccine. An impairment loss of RMB314.7 million was recognized for long-term assets related to the pneumonia vaccine. The relevant valuation inputs and assumptions were reasonably determined based on the latest information available as of the Reporting Period.

By order of the Board
AIM Vaccine Co., Ltd.
Chairman of the Board and CEO
Mr. Yan ZHOU

Hong Kong, June 5, 2026

As at the date of this announcement, the Board comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Shaojun JIA, Mr. Wen GUAN and Mr. Jie ZHOU as executive directors; Mr. Jichen ZHAO as a non-executive director; and Professor Ker Wei PEI, Ms. Jie WEN and Mr. Xiaoguang GUO as independent non-executive directors.